SNY

Winners After Novo Nordisk’s Insulin Rejection

Eli Lilly and Sanofi look like the biggest players that are best suited to benefit from Novo Nordisk's diabetes-drug setback, but a smaller player could emerge, too. More

Little News, Little Wiggle — Monday’s IP Market Recap

A slow Monday featured a lack of economic or earnings news and led investors to mostly sit on the sidelines for the day. More

12 Intraday Movers and Shakers

Federal regulators have sent a much-hyped Novo Nordisc (NVO) drug back to the drawing board...which is great for competitors like Sanofi (SNY) More

Zoetis: The Biggest IPO Since Facebook

Pfizer's animal health division, Zoetis, could raise more than $2 billion, making it the largest IPO since Facebook. Here's a look at the Zoetis deal, as well as three others on tap for this week. More

Flu’s Pain Is All Gain for These Companies

As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers. More

Flu Season: Where Investors Can Find Relief

This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them. More

Big Pharma: 2012-13′s Flu Vaccine Field

Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season. More